5 research outputs found
Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso.
Traceability is an essential tool for haemovigilance and transfusion safety. In Burkina Faso, the implementation of haemovigilance has been achieved as part of a pilot project from 2005 to 2009. Our study aims to evaluate the traceability of blood transfusions and reporting of adverse reactions over the 6-year postpilot phase. A cross-sectional study including all blood units ordered between 2010 and 2015 has been conducted in public and private health care facilities supplied with blood products by the transfusion center of Bobo-Dioulasso. The complete traceability was possible for 83.5% of blood units delivered. Adverse reactions were reported in 107 cases representing 2.1/1,000 blood units per annum. Transfusions of wrong blood to wrong patient were reported in 13 cases. Our study shows that the haemovigilance system in Burkina Faso must be improved. Healthcare workers have to be sensitized on how traceability and haemovigilance could impact the quality of care provided to patients
Implementation of Blood and Blood Product Regulation Training Workshop, South Africa
The training workshop on Implementation of Blood and Blood Product Regulation was organised and co-hosted by the Paul-Ehrlich -Institut Global Health Protection Program BloodTrain and the Africa Society for Blood Transfusion (AfSBT) from the 20th to the 22nd of August 2019. This was aimed at strengthening the capacity of African countries in developing and implementing regulatory systems for blood. Over thirty participants from countries across the African continent came together in Johannesburg, South Africa and shared knowledge and experiences among themselves and also with experts from the BloodTrain, Africa Society for Blood Transfusion (AfSBT), World Health Organization (WHO) and the New Partnership for Africa`s Development (NEPAD). The workshop addressed a wide range of topics ranging from standards in transfusion, clinical practice, regulatory framework for blood, WHO guidelines related to blood regulation, haemovigilance and regulatory oversight of associated Medical Devices In-vitro Diagnostics. In addition to the context and motivation of the workshop, this report summarises the key content covered throughout the workshop and recommendations for further improvement.Un atelier de formation portant sur la mise en oeuvre de la réglementation du sang et des produits sanguin s a été co-organisé par le programme de protection de la santé mondiale Paul-Ehrlich-Institut BloodTrain et la Société Africaine de Transfusion Sanguine (SATS) du 20 au 22 août 2019. Il visait à renforcer la capacité des pays africains à élaborer et à mettre en oeuvre des systèmes de réglementation pour le sang. Plus de trente participants de pays du continent africain se sont réunis à Johannesburg, en Afrique du Sud et ont partagé leurs connaissances et leurs expériences entre eux ainsi qu'avec des experts de BloodTrain, de la SATS, de l'Organisation Mondiale de la Santé (OMS) et du Nouveau partenariat pour le développement de l'Afrique (NEPAD). L'atelier a abordé un large éventail de sujets, allant des normes de transfusion, de la pratique clinique, du cadre réglementaire pour le sang, des directives de l'OMS relatives à la régulation du sang, à l'hémovigilance et à la surveillance réglementai re des diagnostics in vitro des dispositifs médicaux associés. En plus du contexte et de la motivation de l'atelier, ce rapport résume le contenu clé couvert tout au long de l'atelier et des recommandations pour de nouvelles améliorations
Recommended from our members
Transfusion safety on the African continent: an international quality control of virus testing in blood banks.
BackgroundFollowing World Health Organization recommendations that a quality control (QC) system be implemented in African blood centers, a pilot study of the performance of human immunodeficiency virus antibody (anti-HIV), hepatitis B surface antigen (HBsAg), and hepatitis C virus antibody (anti-HCV) testing by several Sub-Saharan African blood centers was initiated.Study design and methodsA reference laboratory sent a panel of 25 samples to six African blood center laboratories. The panel included eight negative samples; four anti-HIV-1–, one anti-HIV-2–, four anti-HCV–, and five HBsAg-positive samples; and three samples consisting of mixtures of two sera to mimic coinfections. Sensitivity, specificity, and overall quality (correct positive or negative status) scores were calculated.ResultsFrom the 21 sets of results obtained (seven for each virus), eight were from rapid tests (two for HIV, three for HBV, and three for HCV) and 13 were from enzyme immunoassays (EIAs; all HIV EIAs were antigen/antibody combination assays). Overall assay sensitivity was 98% for HIV, 75% for HBV, and 88% for HCV; agreement between blood centers using the same assay was good. Sensitivity of rapid tests was notably poorer than EIAs, with overall sensitivity quality scores of 64.5% for rapid tests (20% for HBsAg rapid tests) compared to 100% for EIAs. The overall specificity quality scores were 98.3 and 94.5% for EIAs and rapid tests, respectively.ConclusionsThis pilot QC study organized for blood centers of Sub-Saharan Africa showed the feasibility of the approach despite some logistic constraints. Although interlaboratory variability was small, the poor performance of rapid tests, especially for HBsAg, raises policy questions about their use as the only screening assay
Traceability of Blood Transfusions and Reporting of Adverse Reactions in Developing Countries: A Six-Year Postpilot Phase Experience in Burkina Faso
Recommended from our members
Estimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study.
BackgroundSub-Saharan Africa remains the epicenter of the human immunodeficiency virus (HIV) pandemic. However, there is a lack of multicenter data on the risk of transfusion-transmitted HIV from blood centers in sub-Saharan Africa.Study design and methodsThe incidence of HIV infections in the blood donations collected in the main blood banks of five countries (Burkina Faso, Congo, Ivory Coast, Mali, and Senegal) was determined to estimate the current transfusion risk of HIV infection using the incidence rate/window period model.ResultsThe risk of transfusion-transmitted HIV infections associated with the window period varied from 1 in 90,200 donations (Senegal) to 1 in 25,600 (Congo). Considering the five participating blood centers as a whole, the incidence rate of HIV-positive donors per 100,000 person-years was 56.6 (95% confidence interval [CI], 47.1-67.9); the residual risk (RR) was 34.1 (95% CI, 7.8-70.7) per 1 million donations, which represents 1 in 29,000 donations (95% CI, 1/128,000-1/14,000).ConclusionRR estimates varied according to the country. This is potentially due to a lower incidence of HIV infection in the general population or to a more efficient selection of blood donors in the countries with the lowest risk. The estimates of the transfusion risk of HIV infection in each country are important, both to assess the impact of current preventative strategies and to contribute data to policy decisions to reinforce transfusion safety